Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label extension study of inhaled treprostinil in fibrotic lung disease
MOH_2023-07-10_012802Phase 3Recruiting
- Sponsor
- United Therapeutics Corporation
- Start
- Apr 2023
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of treprostinil in idiopathic pulmonary fibrosis (IPF) and pulmonary fibrosis (PF), sponsored by United Therapeutics Corporation. Primary endpoint: Long-term safety of inhaled treprostinil. Started Apr 2023; status: recruiting.
02
Drugs
treprostinil
03
Conditions
idiopathic pulmonary fibrosis (IPF)pulmonary fibrosis (PF)
Beyond the preview
Go deeper on MOH_2023-07-10_012802.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2023-07-10_012802.